DZ 002
Alternative Names: DZ-002Latest Information Update: 27 Aug 2021
At a glance
- Originator Da Zen Theranostics
- Class Antineoplastics; Drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Lymphoma; Solid tumours
Most Recent Events
- 01 Aug 2021 Phase-I clinical trials in Lymphoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (IV) (NCT04970992)
- 01 Aug 2021 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT04970992)
- 28 Jul 2021 Da Zen Theranostics plans a phase I trial in Solid tumours and Lymphomas (Late-stage disease, Metastatic disease, Inoperable/unresectable, Second-line therapy or greater), in the US, In July 2021 (Parenteral)(NCT04970992)